Prime Medicine (PRME) Return on Capital Employed: 2022-2025
Historic Return on Capital Employed for Prime Medicine (PRME) over the last 3 years, with Sep 2025 value amounting to -0.69%.
- Prime Medicine's Return on Capital Employed rose 19.00% to -0.69% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.69%, marking a year-over-year increase of 19.00%. This contributed to the annual value of -0.97% for FY2024, which is 5.00% down from last year.
- According to the latest figures from Q3 2025, Prime Medicine's Return on Capital Employed is -0.69%, which was up 9.38% from -0.76% recorded in Q2 2025.
- Over the past 5 years, Prime Medicine's Return on Capital Employed peaked at -0.43% during Q1 2023, and registered a low of -1.28% during Q4 2023.
- Its 3-year average for Return on Capital Employed is -0.79%, with a median of -0.76% in 2025.
- Its Return on Capital Employed has fluctuated over the past 5 years, first slumped by 83bps in 2023, then spiked by 55bps in 2024.
- Over the past 4 years, Prime Medicine's Return on Capital Employed (Quarterly) stood at -0.45% in 2022, then crashed by 83bps to -1.28% in 2023, then soared by 55bps to -0.73% in 2024, then rose by 19bps to -0.69% in 2025.
- Its Return on Capital Employed stands at -0.69% for Q3 2025, versus -0.76% for Q2 2025 and -0.74% for Q1 2025.